Sugi Predict

Sugi Predict / Compounds / SCHEMBL1378090

SCHEMBL1378090

SCHEMBL1378090

Fc1c(Cl)c(-c2ccccc2)cc2c(Nc3cccc(C(F)(F)F)c3)n[nH]c12

nearest known ligand 0.53

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ GSK3B P49841 2/20 0.53
▸ CDK1 P06493 1/20 0.53
▸ CDK2 P24941 1/20 0.53
▸ FADS1 O60427 1/20 0.49
▸ ABCG2 Q9UNQ0 6/20 0.47
▸ GRM4 Q14833 1/20 0.45
▸ CTSC P53634 2/20 0.44
▸ AURKB Q96GD4 1/20 0.44
▸ IDH2 P48735 1/20 0.43
▸ EGFR P00533 1/20 0.42
▸ TRPA1 O75762 2/20 0.42
▸ TSHR P16473 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ PDGFRB P09619 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6528861 0.95 CDK1 (0.49) GSK3BCDK1CDK2FADS1ABCG2
SCHEMBL2336016 0.89 GSK3B (0.55) GSK3BCDK1CDK2FADS1ABCG2
SCHEMBL2335033 0.89 GSK3B (0.52) GSK3BCDK1CDK2FADS1ABCG2
SCHEMBL2334773 0.88 GSK3B (0.62) GSK3BCDK1CDK2FADS1TRPA1
SCHEMBL1376202 0.85 GSK3B (0.49) GSK3BCDK1CDK2FADS1ABCG2
SCHEMBL2336269 0.84 GSK3B (0.55) GSK3BCDK1CDK2EGFR
SCHEMBL2333075 0.83 GSK3B (0.57) GSK3BCDK1CDK2FADS1ABCG2
SCHEMBL2335459 0.82 GSK3B (0.55) GSK3BCDK1CDK2FADS1ABCG2
SCHEMBL1376062 0.82 GSK3B (0.59) GSK3BCDK1CDK2FADS1ABCG2
SCHEMBL4509554 0.81 FADS1 (0.59) GSK3BCDK1CDK2FADS1ABCG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4764168-B2 — — 2011-08-31 — — JP claimed
EP-1572200-B1 AMINOINDAZOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2011-08-17 — — EP claimed
CN-101979382-A Aminoindazole derivatives and use thereof as kinase inhibitors AVENTIS PHARMA SA 2011-02-23 — — CN claimed
US-7629374-B2 Use of aminoindazole derivatives for the inhibition of tau phosphorylation AVENTIS PHARMA SA (FR) 2009-12-08 — — US claimed
US-20080261997-A1 USE OF AMINOINDAZOLE DERIVATIVES FOR THE INHIBITION OF TAU PHOSPHORYLATION AVENTIS PHARMA S.A. (FR) 2008-10-23 — — US claimed
US-7019011-B2 Aminoindazole derivatives as medicaments and pharmaceutical compositions including them AVENTIS PHARMA S.A. (FR) 2006-03-28 — — US claimed
CN-1713909-A Aminoindazole derivatives and their use as kinase inhibitors AVENTIS PHARMA SA (FR) 2005-12-28 — — CN claimed
EP-1572200-A1 AMINOINDAZOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS Aventis Pharma S.A. (FR) 2005-09-14 — — EP claimed
WO-2004062662-A1 AMINOINDAZOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2004-07-29 — — WO claimed
US-20040132794-A1 Novel aminoindazole derivatives as medicaments and pharmaceutical compositions including them AVENTIS PHARMA S.A. (FR) 2004-07-08 — — US claimed
EP-1572200-B1 AMINOINDAZOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2011-08-17 — — EP disclosed
CN-101979382-A Aminoindazole derivatives and use thereof as kinase inhibitors AVENTIS PHARMA SA 2011-02-23 — — CN disclosed
US-7629374-B2 Use of aminoindazole derivatives for the inhibition of tau phosphorylation AVENTIS PHARMA SA (FR) 2009-12-08 — — US disclosed
US-20080261997-A1 USE OF AMINOINDAZOLE DERIVATIVES FOR THE INHIBITION OF TAU PHOSPHORYLATION AVENTIS PHARMA S.A. (FR) 2008-10-23 — — US disclosed
US-7407981-B2 Aminoindazole derivatives as medicaments and pharmaceutical compositions including them AVENTIS PHARMA S.A. (FR) 2008-08-05 — — US disclosed
US-7196109-B2 Aminoindazole derivatives as medicaments and pharmaceutical compositions including them AVENTIS PHARMA SA (FR) 2007-03-27 — — US disclosed
US-20060074122-A1 Novel aminoindazole derivatives as medicaments and pharmaceutical compositions including them AVENTIS PHARMA S.A. (FR) 2006-04-06 — — US disclosed
US-7019011-B2 Aminoindazole derivatives as medicaments and pharmaceutical compositions including them AVENTIS PHARMA S.A. (FR) 2006-03-28 — — US disclosed
CN-1713909-A Aminoindazole derivatives and their use as kinase inhibitors AVENTIS PHARMA SA (FR) 2005-12-28 — — CN disclosed
US-20040132794-A1 Novel aminoindazole derivatives as medicaments and pharmaceutical compositions including them AVENTIS PHARMA S.A. (FR) 2004-07-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261997-A1 USE OF AMINOINDAZOLE DERIVATIVES FOR THE INHIBITION OF TAU PHOSPHORYLATION OXSR1, CBR1, OXER1 GSK3B 159/4885CDK1 63/4885CDK2 549/4885
US-20040132794-A1 Novel aminoindazole derivatives as medicaments and pharmaceutical compositions including them SIGMAR1, CYP2C8, CNR1 GSK3B 3595/4885CDK1 2123/4885CDK2 2237/4885
US-20060074122-A1 Novel aminoindazole derivatives as medicaments and pharmaceutical compositions including them CNR1, SUCNR1, CBR1 GSK3B 3542/4885CDK1 1006/4885CDK2 1855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.